American Head & Neck Society

Advancing Education, Research, and Quality of Care for the Head and Neck oncology patient.

  • About
    • Mission Statement and Purpose
    • Divisions & Services of the Society
      • Education
        • Scientific Program/Resident Courses
        • Surgical Videos
        • Journal Club
        • Journals
        • Global Outreach
        • Awards
          • Margaret F. Butler Award
      • Diversity, Equity and Inclusion Division
      • Patient Care
        • Cancer Survivorship
          • Patient Education on Post-Treatment Care
          • Interviews with Cancer Survivors
        • Cancer Prevention
          • SLIDE DECK: HPV-Related Oropharyngeal Cancer
        • Guidelines/Position Statements
        • Find-A-Physician
      • Research
        • Grant Information
        • Clinical Trial
        • Tissue Banks
      • Administrative Division
        • AHNS Process for Evaluating Projects Requiring Funding
    • Leadership
    • History
      • Society Background
      • AHNS History Interviews
      • Past Presidents
      • In Memory
    • AHNS Newsletter
    • Professionalism & Ethics
    • AHNS Policies and Procedures (P&P) Manual
    • AHNS Foundation
    • AHNS Bylaws
    • AHNS Staff
    • AHNS News and Announcements
    • COVID-19 Bulletin Board
  • Heads Up!
  • Post a Job
  • Meetings
    • AHNS Virtual Education Series
      • TORS Webinar Series
    • AHNS Meetings Info
    • AHNS Call For Abstracts
    • Past Meetings
    • Related Meetings
  • For Patients
  • For Trainees
    • Fellowship Curriculum for FY2024-2025
      • For Current AHNS Fellows
      • Certificate of Completion Request
    • Accredited Fellowships
      • Directory of Fellowships
      • AHNS Fellowship Match
      • Fellowship Curriculum
      • Fellowship Graduates
      • For Program Directors
    • AHNS Surgical Videos
    • Fellows’ Virtual Tumor Boards
    • Cutaneous Cancer
  • Sections
    • Endocrine Surgery
    • Skull Base Surgery Section
    • Reconstructive Head & Neck Surgery
      • Head and Neck Reconstruction- Information for Patients
    • Mucosal Malignancy Section
      • Mucosal Malignancy Section Patient Information
    • Salivary Gland Section
      • Salivary Gland Section Patient Education Handout: Parotidectomy
    • Cutaneous Cancer
  • Find-A-Physician
  • Member Central
    • Join AHNS
    • Find-A-Physician
    • Mailing List Order
  • Login
    • Password Reset
  • Donate

Published on November 6, 2018 by Laura Goguen

Laura Goguen – Boston, MA

Practice Contact Information

Dana Farber Cancer Institute & Brigham and Women's Hospital
15 Frances Street

Boston
MA
02115
United States

Phone:
Email:
Web Site:


Areas of surgical specialization in Head and Neck Surgery

Head and Neck Surgeon


Biography/Statement

Dr. Laura Goguen, MD is a Board Certified Otolaryngologist specializing in Head and Neck Surgery. She graduated from the College Of Human Medicine at Michigan State University in 1990 and completed her residency in otolaryngology at Boston University/Tufts University Combined Program in 1995. She was Assistant Professor at Case Western Reserve University School of Medicine from 1995-1997.  She joined the faculty at Harvard Medical School in 1997 and has been treating head and neck cancer patients at Brigham and Women’s Hospital and Dana Farber Cancer Institute and teaching Harvard Medical Students and Harvard Otolaryngology Residents. She is an Associate Professor and she has been actively involved in numerous clinical trials and research endeavors. Her clinical areas of interest include ablative head and neck cancer surgery, thyroid nodules and malignancy, salivary gland tumors, mucosal and skin malignancies and sinonasal malignancies.

Clinical Trials

Bibliography

Published on October 30, 2018 by Dinesh Chhetri

Dinesh Chhetri – Los Angeles, CA

Practice Contact Information

University of California, Los Angeles
10833 Le Conte Avenue

Los Angeles
CA
90095
United States

Phone: (310) 794-4225
Email:
Web Site: https://www.uclahealth.org/head-neck-surgery/cancer-program


Areas of surgical specialization in Head and Neck Surgery

Head and Neck Research, Head and Neck Surgeon


Biography/Statement

Dinesh Chhetri, MD, FACS, is a Professor and Vice Chair of Clinical Affairs in the Department of Head and Neck Surgery at the University of California, Los Angeles (UCLA).  He obtained his medical degree, residency training in otolaryngology, and fellowship training in Laryngology all at UCLA.  He is a dedicated head and neck surgeon with clinical and research interests in HPV related head and neck cancer, laryngeal cancer, and functional preservation after head and neck cancer treatment. He is the director of the UCLA Swallowing Disorders Program, the UCLA Head and Neck Cancer Survivorship Program and co-director of the UCLA Laryngology (Voice) program.

Clinical Trials

Bibliography

Published on October 23, 2018 by Steven Chinn

Steven Chinn – Ann Arbor, Michigan

Practice Contact Information

University of Michigan
1500 East Medical Center Drive

Ann Arbor
Michigan
48109
United States

Phone: 734-232-0120
Email:
Web Site: https://www.uofmhealth.org/profile/4430/steven-bennett-chinn-md


Areas of surgical specialization in Head and Neck Surgery

Head and Neck Research, Head and Neck Surgeon, Reconstructive Head & Neck Surgery


Biography/Statement

Dr. Steven Chinn received his medical degree from the Keck School of Medicine at the University of Southern California in 2008, graduating with Senior Honors and elected into the National Alpha Omega Alpha Honor Medical Society. He completed his post-graduate surgical training in Otolaryngology-Head and Neck Surgery at the University of Michigan in 2014 during which he completed an 18-month NIH funded research fellowship in the Molecular Genetics and Cellular Biology of Head and Neck Cancer. He then completed a two-year dual fellowship in Head & Neck Surgical Oncology and Microvascular Reconstructive Surgery at the University of Texas MD Anderson Cancer Center. Dr. Chinn also holds a graduate degree (MPH) in Molecular Epidemiology from the University of Michigan School of Public Health.

Dr. Chinn joined the faculty at the University of Michigan in 2016, and currently serves as an Assistant Professor in the Department of Otolaryngology-Head and Neck Surgery. He is a member of the Head and Neck Oncology Division, an active member of the Head and Neck Oncology Translational Research Program, and a member of the University of Michigan Comprehensive Cancer Center. His clinical expertise is in the treatment of all types of head and neck cancer, including minimally invasive robotic surgery and complex oral cancers. He also specializes in complex reconstructive surgery to restore form and function after cancer treatment. His research interests include molecular genetics of oral cavity cancer, head and neck cancer stem cells, the molecular mechanisms of metastasis, and outcomes research with an emphasis on improving survival and functional status.

Clinical Trials

Randomized Phase II study of DCE-MRI-based dose escalation for poor-prognosis head and neck cancer (Phase II)
Primary Investigator: Mierzwa, Michelle
This study aims to improve locoregional control of poor prognosis Head and Neck Cancer (HNC) patients by selectively escalating the radiotherapy dose to subvolumes of tumor likely to be resistant to standard Radiation Therapy (RT) using DCE-MRI (Dynamic Contrast Enhanced Magnetic Resonance Imaging). Standard doses of radiotherapy to the rest of the tissues and surrounding normal tissues will be maintained.

VISmodegib for ORbital and periocular Basal cell carcinoma (VISORB) (Phase IV)
Primary Investigator: Kahana, Alon
Basal cell carcinoma (BCCA) is the most common human cancer, and frequently affects facial structures. While rarely fatal, facial BCCA can be disfiguring and expensive to treat. ;Vismodegib is a small molecule inhibitor of SMO developed for the treatment of tumors in which the Hh signaling pathway appears to contribute to the development and maintenance of tumorigenesis. Vismodegib was recently approved by the Food and Drug Administration (FDA) for treatment of metastatic and locally advanced BCCA. Recent reports have suggested that vismodegib treatment for orbital BCCA may facilitate eye preservation even if surgery is eventually required ;In order to assess the potential of vismodegib to improve the ophthalmic outcomes following treatment for orbital and/or periocular BCCA, this study will follow patients with globe-threatening orbital and lacrimal-threatening periocular BCCA who are being treated with vismodegib as standard of care.

Pain Control Using Neuromodulation in Patients Undergoing Definitive Chemoradiotherapy or Radiation Therapy for Locally Advanced Head and Neck Cancer (Phase II)
Primary Investigator: Dasilva, Alexandre
The purpose of this study is to determine if Transcranial Direct Current Stimulation (tDCS) can reduce pain perception associated with the effects of receiving definitive radiation therapy or chemoradiotherapy in head and neck cancer (HNCa) patients.

A Phase I, open-label, dose escalation study of oral LGK974 in patients with malignancies dependent on Wnt ligands (Phase I)
Primary Investigator: Smith, David
This primary purpose of this study is to find the recommended dose of LGK974 that can be safely given to adult patients with maliganacies dependent on Wnt ligands for whom no effective standard treatment is available.

A phase 1, open-label, dose-escalation study of SEA-CD40 in adult patients with advanced malignancies (Phase I)
Primary Investigator: Smith, David
This study will examine the safety profile of SEA-CD40. The study will test increasing doses of SEA-CD40 given at least every 3 weeks to small groups of patients. The goal is to find the highest dose of SEA-CD40 that can be given to patients that does not cause unacceptable side effects. The pharmacokinetics, pharmacodynamic effects, biomarkers of response, and antitumor activity of SEA-CD40 will also be evaluated.

RANDOMIZED PHASE II/III TRIAL OF SURGERY AND POSTOPERATIVE RADIATION DELIVERED WITH CONCURRENT CISPLATIN VERSUS DOCETAXEL VERSUS DOCETAXEL AND CETUXIMAB FOR HIGH-RISK SQUAMOUS CELL CANCER OF THE HEAD AND NECK (Phase II/III)
Primary Investigator: Worden, Francis
This randomized phase II/III trial studies how well radiation therapy works when given together with cisplatin compared to docetaxel or cetuximab and docetaxel after surgery in treating patients with stage III-IV squamous cell head and neck cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or transmit tumor killing molecules to them. It is not yet known whether radiation therapy is more effective when given with cisplatin, docetaxel, or cetuximab and docetaxel.

The validation of a novel adherence method for oral oncolytics (N/A)
Primary Investigator: Kraft, Shawna

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies (Phase I)
Primary Investigator: Alva, Ajjai
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families. In this study, MGCD516 is orally administered to patients with advanced solid tumor malignancies to evaluate its safety, pharmacokinetic, metabolism, pharmacodynamic and clinical activity profiles. ;During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed; during the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected patient populations. ;Patients anticipated to be enrolled in Phase 1b will be selected based upon having a tumor type, including but not limited to, non small cell lung cancer and head and neck cancer positive for specific activating MET, NTRK2, NTRK3, or DDR2 mutations, MET or KIT/PDGFRA/KDR gene amplification, selected gene rearrangements involving the MET, RET, AXL, NTRK1, or NTRK3 gene loci, or having loss of function mutations in the CBL gene. In addition patients with clear cell renal cell carcinoma refractory to angiogenesis inhibitors or metastatic prostate cancer with bone metastasis will be enrolled.

RANDOMIZED PHASE II AND PHASE III STUDIES OF INDIVIDUALIZED TREATMENT FOR NASOPHARYNGEAL CARCINOMA BASED ON BIOMARKER EPSTEIN BARR VIRUS (EBV) DEOXYRIBONUCLEIC ACID (DNA) (Phase II/III)
Primary Investigator: Worden, Francis
There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in treating patients with nasopharyngeal cancer.

Molecular Analysis for Therapy Choice (MATCH) (Phase II)
Primary Investigator: Alva, Ajjai
This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumors particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.

Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients with HPV+ Oropharyngeal Squamous Cell Cancer (Phase II)
Primary Investigator: Worden, Francis
Investigators will determine whether treatment stratification by neck dissection, to more accurately pathologically stage patients, minimizing the number of treatment modalities in patients with low risk oropharyngeal squamous cell carcinoma, can improve quality of life.

Non-Comparative, Open-label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors (Phase I/II)
Primary Investigator: Lao, Christopher
The purpose of this study to investigate the safety and efficacy of using nivolumab, and nivolumab in combination with ipilimumab, to treat subjects who have virus-associated tumors. Certain viruses that infect human cells have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drugs nivolumab, and nivolumab in combination with ipilimumab, in human subjects who have the following types of tumors: Epstein Barr Virus (EBV) positive gastric cancer; EBV positive nasopharyngeal cancer (NPC); Human Papilloma Virus (HPV) positive cervical, vaginal, vulvar cancer; HPV positive squamous cell cancer of the head and neck (SCCHN); and Polyomavirus positive merkel cell cancer.

Phase II Investigation of Adjuvant Combined Cisplatin and Radiation with Pembrolizumab in Resected HNSCC (Phase II)
Primary Investigator: Worden, Francis

Phase II Expansion Trial Evaluating Axitinib in Patients with Unresectable Recurrent, or Metastatic Head and Neck Cancer utilizing Choi Response Criteria (Phase II)
Primary Investigator: Worden, Francis
This study will be a prospective, single-institution, single-arm phase II study of Axitinib in patients with unresectable recurrent and metastatic head and neck squamous cell carcinoma. The subjects will be started on treatment with 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities. This will be followed by clinical and/or radiologic response assessment after 8 weeks and subsequently every 2 months until disease progression or intolerable toxicity.

An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (Phase III)
Primary Investigator: Worden, Francis
The main purpose of this study is to compare nivolumab and ipilimumab with the Extreme study regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer

Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) (Phase II)
Primary Investigator: Worden, Francis
;This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IV squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if radiation therapy is more effective with or without cisplatin in treating patients with squamous cell carcinoma of the head and neck.

Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) (Phase II)
Primary Investigator: Worden, Francis
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IV squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if radiation therapy is more effective with or without cisplatin in treating patients with squamous cell carcinoma of the head and neck.

Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients with Incurable SCCHN (Phase I/II)
Primary Investigator: Worden, Francis

An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies with HRAS Mutations (Phase II)
Primary Investigator: Worden, Francis

A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412) (Phase III)
Primary Investigator: Worden, Francis

DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS (Phase II)
Primary Investigator: Zalupski, Mark

A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy.(Phase II)
Primary Investigator: Worden, Francis
The purpose of the study is to evaluate the efficacy, safety and tolerability of topically administered AG013 compared to placebo for reducing Oral Mucositis (OM) in patients undergoing chemoradiation for the treatment of head and neck cancer.

A Multi-Center open label single arm phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma (Phase II)
Primary Investigator: Swiecicki, Paul

A Phase 1a Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of OMP-336B11 Administered as a Single Agent to Subjects with Locally Advanced or Metastatic Solid Tumors (Phase I)
Primary Investigator: Smith, David

A MULTI-CENTER PHASE II TRIAL OF INDIVIDUALIZED ADAPTIVE DE-ESCALATED RADIOTHERAPY USING PRE and MID-TREATMENT FDG-PET/CT FOR HPV-RELATED OROPHARYNX CANCER (Phase II)
Primary Investigator: Mierzwa, Michelle

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin (Phase II/III)
Primary Investigator: Worden, Francis

Bibliography

https://www.ncbi.nlm.nih.gov/sites/myncbi/1XkZa-bRdFEAz/bibliography/50848541/public/?sort=date&direction=ascending

  1. Chinn SB, Lee FT Jr, Kennedy GD, Chinn C, Johnson CD, Winter TC 3rd, Warner TF, Mahvi DM. Effect of vascular occlusion on radiofrequency ablation of the liver: results in a porcine model. American Journal of Roentgenology. 2001 Mar; 176(3):789-95.
  2. Liu TJ, Lai HC, Wu W, Chinn S, Wang PH. Developing a strategy to define the effects of insulin-like growth factor-1 on gene expression profile in cardiomyocytes. Circulation Research. 2001 Jun 22;88(12):1231-8.
  3. Floyd JA, Gold DA, Concepcion D, Poon TH, Wang X, Keithley E, Chen D, Ward EJ, Chinn SB, Friedman RA, Yu HT, Moriwaki K, Shiroishi T, Hamilton BA.A natural allele of Nxf1/TAP suppresses retroviral insertion mutations. Nature Genetics. 2003 Nov;35(3):221-8. Epub 2003 Sep 28.
  4. Sinha UK, Mazhar K, Chinn SB, Liu L, Masood R, Rice DH, Gill PS. EphB4 is a poor prognostic factor in HNSCC and its correlate with smoking and survival. Arch Otolaryngol Head Neck Surg. 2006 Oct; 132(10): 1053-9.
  5. Sinha UK, Schorn VJ, Hochstim C, Chinn SB, Zhu S, Masood R. Increased radiation sensitivity of head and neck squamous cell carcinoma with sphingosine kinase 1 inhibition. Head & Neck. 2010 May. doi: 10.1002/hed.21418.
  6. Spector ME, Chinn SB, Wolf GT, Chepeha DB, Carey TE, Prince ME, Worden F Bradford CR. Diagnostic Modalities for Distant Metastasis in Head and Neck Squamous Cell Carcinoma: Are We Changing Life Expectancy? Laryngoscope 2012. Jul; 122(7):1507-11. doi: 10.1002/lary.23264.
  7. Chinn SB, Darr OA, Peters RD, Prince ME. Role of Head and Neck Squamous Cell Carcinoma Cancer Stem Cells in Tumorigenesis, Metastasis and Treatment Failures. Frontiers in Endocrinology 2012 Aug 3;3:90. doi: 10.3389/fendo.2012.00090.
  8. Wang AC, Chinn SB, Than KD, Telian SA, Arts HA, El-Kashlan H, Thompson BG. Durability of hearing preservation after microsurgical treatment of vestibular schwannoma using the middle cranial fossa approach. Journal of Neurosurgery. 2013 Jul; 119(1):131-8. doi: 10.3171/2013.1.JNS1297.
  9. Spector ME, Gallagher KK, Bellile E, Chinn SB, et al. Patterns of nodal metastasis and prognosis in human papillomavirus positive oropharyngeal squamous cell carcinoma. Head Neck. 2013 Aug 3. doi: 10.1002/hed.23438.
  10. Lin GC, Scheel A, Akkina S, Chinn S, et al. Epidermal growth factor receptor, p16, cyclin D1, and p53 staining patterns for inverted papilloma. Int Forum Allergy Rhinol. 2013 Nov;3(11):885-9. doi: 10.1002/alr.21215.
  11. Chinn SB, Spector ME, Bellile EL, Lin T, Prince ME, Bradford CR, Wolf GT, Carey TE, Eisbruch A, Chepeha DB. Perineural invasion in the pN0 neck in OCSCC. Otolaryngol Head Neck Surg. 2013 Dec; 149(6):893-9. doi: 10.1177/0194599813506867.
  12. Chinn SB, Collar RM, McHugh JB, Hogikyan ND, Thorne MC. Pediatric laryngeal neurofibroma: Case report and review of the literature. Int J Pediatr Otorhinolaryngol. 2013 Nov 13. doi:pii: S0165-5876(13)00533-8.
  13. Chinn SB, Spector ME, Light E, Lin T, Teknos TN, Prince ME, Bradford CR, Wolf GT, Urba S, Worden F, Carey TE, Eisbruch A, Chepeha DB. Induction chemotherapy for organ preservation versus surgery for advanced oral cavity squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2013 Dec 26. doi: 10.1001 PMID: 24370563
  14. Chinn SB, Darr OA, Owen JH, Light E, Carey TE, Prince ME. Head and neck squamous cell carcinoma cancer stem cells: tumorigenesis and metastasis in an orthotopic mouse model. Head and Neck. 2014 Jan 10. doi: 10.1002/hed.23600. [Epub ahead of print]
  15. Lin GC, Akkina S, Chinn S, Prince ME, Mchugh JB, Carey T, Zacharek MA. Sinonasal inverted papilloma: prognostic factors with emphasis on resection margins. J Neurol Surg B Skull Base. 2014 Apr;75(2):140-6. doi: 10.1055/s-0033-1363169. Epub 2014 Feb 17.
  16. Spector ME, Chinn SB, Bellile E, Gallagher KK, Ibrahim M, Cainshtein J, Chanowski EJP, Walline HM, Moyer JS, Prince ME, Wolf GT, Bradford CR, McHugh JB, Carey TE, Worden FP, Eisbruch A, Chepeha DB. Matted Nodes Predict Distant Metastasis in Advanced Stage III/IV Oropharyngeal Squamous Cell Carcinoma. Head Neck. 2014 Sep 23. doi: 10.1002/hed.23882.
  17. Owen JH, Graham MP, Chinn SB, Darr OF, Chepeha DB, Wolf GT, Bradford CR, Carey TE, Prince ME. A novel method of cell line establishment utilizing fluorescence –activated cell sorting resulting in six new head and neck squamous cell carcinoma lines. Head and Neck. 2015 Feb 9. doi: 10.1002/hed.24019.
  18. Chinn SB, Myers JN. Oral Cavity Carcinoma: Current Management, Controversies and Future Directions. Journal of Clinical Oncology. 2015 Oct 10;33(29):3269-76. doi: 10.1200/JCO.2015.61.2929. Epub 2015 Sep 8.
  19. Birkeland AC, Rosko AJ, Chinn SB et al. Prevalence and Outcomes of Head and Neck versus Non-Head and Neck Second Primary Malignancies in Head and Neck Squamous Cell Carcinoma: An Analysis of the Surveillance, Epidemiology, and End Results Database. ORL J Otorhinolaryngol Relat Spec. 2016 Feb 25;78(2):61-69.
  20. Chepeha DB, Spector ME, Chinn SB, et al. Hemiglossectomy tongue reconstruction: Modeling of elevation, protrusion, and functional outcome using receiver operator characteristic curve. Head Neck 2016 Feb 21. doi: 10.1002/hed.24417
  21. Spector ME, Chinn SB, Bellile E, Gallagher KK, Kang SY, Moyer JS, Prince ME, Wolf GT, Bradford CR, McHugh JB, Carey TE, Worden FP, Eisbruch A, Ibrahim M, Chepeha DB. Exploration for an Algorithm for Deintensification to Exclude the Retropharyngeal Site From Advanced Oropharyngeal Squamous Cell Carcinoma Treatment. JAMA Otolaryngol Head Neck Surg. 2016 Feb 18. doi: 10.1001/jamaoto.2015.3602.
  22. Silver NL, Chinn SB, Bradley PJ, Weber RS. Surgery for Malignant Submandibular Gland Neoplasms. Adv Otorhinolaryngol. 2016 April 12.
  23. Moyer JS, Rudy S, Boonstra PS, Kraft C, Chinn SB, Baker SR, Schwartz JL, Bichakjian CK, Fullen D, Durham AB, Lowe L, Johnson TM. Efficacy of Staged Excision with Permanent Section Margin Control for Cutaneous Head and Neck Melanoma. JAMA Dermatol. 2016 Dec 21. doi: 10.1001/jamadermatol.2016.4603.
  24. Walline HM, Komarck C, McHugh JB, Tang AL, Owen JH, Teh BT, McKean EM, Glover T, Graham MP, Prince ME, Chepeha DB, Chinn SB, Ferris RF, Gollin SM, Hoffman TK, Bier H, Brakenhoff R, Bradford CR, Carey TE. Integration of High-Risk Human Papillomavirus into Cellular Cancer-Related Genes in Head and Neck Cancer Cell Lines. Head Neck. 2017 May;39(5):840-852. doi: 10.1002/hed.24729. Epub 2017 Feb 25.
  25. Rosko AJ, Birkeland AC, Chinn SB, Shuman AG, Prince ME, Patel RM, McHugh JB, Spector ME. Survival and Margin Status in Head and Neck Radiation-Induced Sarcomas and De Novo Sarcomas.Otolaryngol Head Neck Surg. 2017 Apr 1:194599817700389. doi: 10.1177/0194599817700389. [Epub ahead of print]
  26. Birkeland AC, Rosko AJ, Beesley L, Bellile E, Chinn SB, Shuman AG, Prince ME, Wolf GT, Bradford CR, Brenner JC, Spector ME. Preoperative Tracheostomy Is Associated with Poor Disease-Free Survival in Recurrent Laryngeal Cancer. Otolaryngol Head Neck Surg. 2017 May 1:194599817709236. doi: 10.1177/0194599817709236.
  27. Chandrasekharappa SC, Chinn SB et al. Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50. Cancer. 2017 Jul 5. doi: 10.1002/cncr.30802. [Epub ahead of print] PubMed PMID: 28678401.
  28. Chinn SB, Zafereo ME, Waguespack SG, Edeiken BS, Roberts DB, Clayman GL. Long-term outcomes of lateral neck dissection in patients with recurrent or persistent well-differentiated thyroid cancer. Thyroid. 2017 Aug 15. doi: 10.1089/thy.2017.0203. [Epub ahead of print] PubMed PMID: 28806882.
  29. Birkeland AC, Beesley L, Bellile E, Rosko AJ, Hoesli R, Chinn SB, Shuman AG, Prince ME, Wolf GT, Bradford CR, Brenner JC, Spector ME. Predictors of survival after total laryngectomy for recurrent/persistent laryngeal squamous cell carcinoma. Head Neck. 2017 Sep 30. doi: 10.1002/hed.24918. [Epub ahead of print] PubMed PMID:28963806
  30. Rosko AJ, Birkeland AC, Bellile E, Kovatch KJ, Miller AL, Jaffe CC, Shuman AG, Chinn SB, Stucken CL, Malloy KM, Moyer JS, Casper KA, Prince MEP, Bradford CR, Wolf GT, Chepeha DB, Spector ME. Hypothyroidism and Wound Healing After Salvage Laryngectomy. Ann Surg Oncol. 2017 Dec 20. doi: 10.1245/s10434-017-6278-4.
  31. Hoesli R, Birkeland AC, Rosko AJ, Issa M, Chow KL, Michmerhuizen NL, Mann JE, Chinn SB, Shuman AG, Prince ME, et al. Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma. Oral Oncol. 2018 Feb;77:83-89. doi: 10.1016/j.oraloncology.2017.12.003. Epub 2017 Dec 23. PubMed PMID: 29362129.
  32. Gingerich MA, Smith JD, Michmerhuizen NL, Ludwig M, Devenport S, Matovina C, Brenner C, Chinn SB. Comprehensive review of genetic factors contributing to head and neck squamous cell carcinoma development in low-risk, nontraditional patients. Head Neck. 2018 Feb 10. doi: 10.1002/hed.25057. [Epub ahead of print] PubMed PMID: 29427520.
  33. Stevens JR, Rosko AJ, Marchiano E, Haring C, Chinn SB, Malloy KM, Prince ME, Casper K, Moyer J, Chepeha D, Stucken CL, Spector ME. The Spider Limb Positioner in subscapular system free flaps. Oral Oncol. 2018 Oct;85:24-28. doi: 10.1016/j.oraloncology.2018.08.004. Epub 2018 Aug 17.
  34. Beesley LJ, Hawkins PG, Amlani LM, Bellile EL, Casper KA, Chinn SB, Eisbruch A, Mierzwa ML, Spector ME, Wolf GT, Shuman AG, Taylor JMG. Individualized survival prediction for patients with oropharyngeal cancer in the human papillomavirus era. Cancer. 2018 Oct 6. doi: 10.1002/cncr.31739. [Epub ahead of print]

Published on October 12, 2018 by Urjeet Patel

Urjeet Patel – Chicago, Illinois

Practice Contact Information

Northwestern University
676 North Saint Clair Street
#1325
Chicago
Illinois
60611
United States

Phone: 3126953222
Email: [email protected]
Web Site:


Areas of surgical specialization in Head and Neck Surgery

Head and Neck Surgeon, Reconstructive Head & Neck Surgery


Biography/Statement

Dr. Patel was born and raised in Chicago and completed his undergraduate education at Brown University where he received his BA in Philosophy.  He attended Yale University for medical school and then completed residency in Otolaryngology—Head and Neck Surgery at Washington University in St. Louis.  He then joined Dr. Richard Hayden at the Mayo Clinic Scottsdale for a fellowship in Head and Neck Oncological and Microvascular Reconstructive Surgery.  He returned to Chicago in 2003 to join the staff at Stroger – Cook County Hospital where he now serves as Chairman of the Division of Otolaryngology and Chairman of the Cancer Committee.  He is recently promoted to full professor in the Department of Otolaryngology at Northwestern University.  He serves on several national committees for the American Head and Neck Society and currently serves as the Chairman of the Reconstructive Surgery Section.  He also participates in multi-institutional clinical trials for cancer treatment through the National Cancer Institute (NCI).  His clinical interests include head and neck oncologic surgery, minimally-invasive transoral robotic surgery (TORS), as well as reconstructive surgery with free tissue transfer.

Clinical Trials

Bibliography

Published on October 10, 2018 by Andrew Coughlin

Andrew Coughlin – Omaha, Nebraska

Practice Contact Information

Nebraska Methodist Hospital Estabrook Cancer Center
8303 Dodge Street

Omaha
Nebraska
68114
United States

Phone: 402-354-5048
Email:
Web Site:


Areas of surgical specialization in Head and Neck Surgery

Endocrine Surgery, Head and Neck Research, Head and Neck Surgeon, Reconstructive Head & Neck Surgery


Biography/Statement

I am a Head and Neck Ablative and Reconstructive Surgeon practicing in Omaha, NE. Our group has one of the largest Head and Neck practices in the country specializing in all aspects of head and neck surgery. I specifically specialize in robotic surgery for HPV positive oropharyngeal cancers, microvascular reconstruction, salivary gland malignancies including sialendoscopy, melanoma/skin cancers and open/endoscopic skull base surgery. I completed my residency training at the University of Texas Medical Branch in Galveston, TX and then went on to complete my fellowship training in Nebraska. I have been in practice 5 years and have become heavily involved in both the American Head and Neck Society as well as the Academy of Otolaryngology-Head and Neck Surgery. I am very interested in survivorship after Head and Neck cancer treatment as well as outcomes research aimed at improving quality of life, efficiencies and decreasing cost of care.

Clinical Trials

Bibliography

Panwar A, Wang F, Lindau R, Militsakh O, Coughlin A, Smith R, Sayles H, Lydiatt D, Lydiatt W. Prediction of Discharge Destination following Laryngectomy. Otolaryngol Head Neck Surg. 2018 Aug 21:194599818792211. doi: 10.1177/0194599818792211. [Epub ahead of print]

Militsakh O, Lydiatt W, Lydiatt D, Interval E, Lindau R, Coughlin A, Panwar A. Development of Multimodal Analgesia Pathways in Outpatient Thyroid and Parathyroid Surgery and Association With Postoperative Opioid Prescription Patterns. JAMA Otolaryngol Head Neck Surg. 2018 Jul 19. doi: 10.1001/jamaoto.2018.0987. [Epub ahead of print]

Berg J, Manosalva RE, Coughlin A, Su YB, Huang TS, Gentry J. Primary intestinal-type adenocarcinoma of the oral tongue: Case report and review of histologic origin and oncologic management. Head Neck. 2018 May 13. doi: 10.1002/hed.25203.

Oltman J, Militsakh O, D’Agostino M, Kauffman B, Lindau R, Coughlin A, Lydiatt W, Lydiatt D, Smith R, Panwar A. Multimodal Analgesia in Outpatient Head and Neck Surgery: A Feasibility and Safety Study. JAMA Otolaryngol Head Neck Surg. 2017 Oct 19. doi: 10.1001/jamaoto.2017.1773.

Aru Panwar, Oleg Militsakh, Robert Lindau, Andrew Coughlin, Harlan Sayles, Katherine R Rieke, William Lydiatt, Daniel Lydiatt, Russell Smith. Impact of Primary Tracheo-Esophageal Puncture on Outcomes after Total Laryngectomy. Otolaryngol Head Neck Surg. 2017 Aug 1:194599817722938. doi: 10.1177/0194599817722938

Smith D, Coughlin A, Qiu S, Underbrink MP.  Inflammatory Myofibroblastic Tumor of the Larynx: A Case Report.  Otolaryngology 5:193. doi: 10.4172/2161-119X.1000193.  (2015)

Coughlin AM, Lindau RH, Militsakh ON.  Use of Chicken Thigh Vessels as a Model for Microsurgical Vessel Coupling.  Annals of Reconstructive, Plastic and Aesthetic Surgery.  July 2015.

Coughlin AM, Pine HS, Baugh R. Lingual Tonsil Abscess with Parapharyngeal Extension: A Case Report. Ear Nose Throat J. 2014 Sep; 93(9): E7-8.  PMID: 25255362

Coughlin AM, Qiu S, Underbrink MP. Management of human papillomavirus-related head and neck cancer. Curr Probl Dermatol. 2014;45:236-5.

Pernas FG, Coughlin AM, Hughes S, Riascos R, Maeso PA.  A Novel use of a Landmark to Avoid Injury of the Anterior Ethmoidal Artery during Endoscopic Sinus Surgery. American Journal of Rhinology and Allergy. January – February 2011; 25(1): 54-7.  PMID: 21711980  

Coughlin A, Resto VA. Oral Cavity Squamous Cell Carcinoma and the Clinically N0 Neck: The Past, Present, and Future of Sentinel Lymph Node Biopsy. Curr Oncol Rep. 2010;12(2):129-35. PMID: 20425598

  • « Previous Page
  • 1
  • …
  • 50
  • 51
  • 52
  • 53
  • 54
  • …
  • 75
  • Next Page »

News and Announcements

  • AHNS YMCP Episode 11 – Melina Windon, MD, Janice Farlow, MD, Eric Gantwerker, MD May 8, 2025
  • Artificial Intelligence in Management of H&N Cancer: New Horizons Presented April 28, 2025
  • A conversation with Dr. Uppaluri: Neoadjuvant Therapy for Advanced H&N Mucosal April 25, 2025
  • The End of April Head and Neck Cancer Awareness Month Approaches! April 23, 2025
  • April is National CBD Awareness Month! April 21, 2025

AHNS Meetings and Events

AHNS 2025 Annual Meeting
Held during the Combined Otolaryngology Spring Meetings (COSM)

May 14-18, 2025
Hyatt Regency New Orleans
New Orleans, Louisiana

learn more...

Contact Us

AHNS, 11300 W. Olympic Blvd, Suite 600
Los Angeles, CA 90064
ph: (310) 437-0559 / fx: (310) 437-0585
[email protected]

Welcome to the AHNS Virtual Repository of Scientific Research

Sections

  • Virtual Repository of Scientific Resources
  • Cell Lines Browse and Search
  • Omics Browse and Search
  • Patient Derived Xenografts Browse and Search
  • Plasmids Browse and Search
  • Pre-Clinical Models Browse and Search
  • Transferable Expertise Browse and Search
  • Transgenic Mice Browse and Search

© 2002–2025 American Head and Neck Society · Privacy and Return Policy
· Managed by BSC Management, Inc